Drug intelligence / Profile preview

OX-NLA

Development stage: Unknown
Lead developer: OxThera
Modality: Small Molecules
Administration: Oral

Overview

OX-NLA is a small molecule drug candidate being developed for the treatment of primary hyperoxaluria. It is designed as a potent inhibitor of glycolate oxidase (GO), an enzyme in the liver responsible for the production of glyoxylate, which is subsequently converted to oxalate. By inhibiting glycolate oxidase, OX-NLA aims to reduce the overproduction of oxalate, thereby preventing the formation of calcium oxalate crystals in the kidneys and urinary tract, which leads to progressive kidney damage and systemic oxalosis. The drug is intended to provide a therapeutic alternative to existing RNA interference (RNAi) therapies by offering a different modality for substrate reduction therapy in patients with Type 1 primary hyperoxaluria (PH1).

Other names: OXNLA

Targets

HAO1 (Glycolate Oxidase)

Beyond the preview

Go deeper on OX-NLA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OX-NLA.

Explore the full profile